Investors pushed shares of

Jabil Circuit

(JBL) - Get Report

higher on Wednesday on reports that two companies will use the electronics manufacturing outsourcer to build their products.

Jabil's stock recently tacked on $1.37, or 5.2% to $27.75.



(PME) - Get Report

, which develops tests to detect cardiovascular disease and cancer, said it had received permission from the U.S. Food and Drug Administration to market its second-generation Point of Care (POC) Skin Sterol Test, which assesses heart disease risk. Jabil will manufacture the product in its U.S. facilities.

In addition, according to media reports,

BenQ Mobile

, based in Munich, has been negotiating with Jabil and


to outsource production of its handsets. BenQ has struggled to make a profit since taking over the business from


(SI) - Get Report

last year.

Jabil representatives were not immediately available for comment.

The company is scheduled to report its fourth-quarter earnings on Tuesday.